key: cord-0794474-lmwfhtyy
authors: Zhang, Chao; Verma, Anurag; Feng, Yuanqing; dos Reis Melo, Marcelo Cardoso; McQuillan, Michael; Hansen, Matthew; Lucas, Anastasia; Park, Joseph; Ranciaro, Alessia; Thompson, Simon; Rubel, Meghan; Campbell, Michael; Beggs, William; Hirbo, Jibril; Mpoloka, Sununguko Wata; Mokone, Gaonyadiwe George; Jones, Marcus; Nyambo, Thomas; Meskel, Dawit Wolde; Belay, Guija; Fokunang, Charles; Njamnshi, Alfred; Omar, Sabah; Williams, Scott; Rader, Daniel; Ritchie, Marylyn; de la Fuente, Cesar; Sirugo, Giorgio; Tishkoff, Sarah
title: Impact of natural selection on global patterns of genetic variation, and association with clinical phenotypes, at genes involved in SARS-CoV-2 infection.
date: 2021-07-27
journal: Res Sq
DOI: 10.21203/rs.3.rs-673011/v1
sha: 8d39d5e42621476e09fa834395f48a82c792eecc
doc_id: 794474
cord_uid: lmwfhtyy

We investigated global patterns of genetic variation and signatures of natural selection at host genes relevant to SARS-CoV-2 infection (ACE2, TMPRSS2, DPP4, and LY6E). We analyzed novel data from 2,012 ethnically diverse Africans and 15,997 individuals of European and African ancestry with electronic health records, and integrated with global data from the 1000GP. At ACE2, we identified 41 non-synonymous variants that were rare in most populations, several of which impact protein function. However, three non-synonymous variants were common among Central African hunter-gatherers from Cameroon and are on haplotypes that exhibit signatures of positive selection. We identify strong signatures of selection impacting variation at regulatory regions influencing ACE2 expression in multiple African populations. At TMPRSS2, we identified 13 amino acid changes that are adaptive and specific to the human lineage. Genetic variants that are targets of natural selection are associated with clinical phenotypes common in patients with COVID-19.

changing variants (Fig. 1A , and Table S2 -3). Twenty-eight (69%), twenty (49%), eighteen (44%), and sixteen (40%) of the nonsynonymous variants were predicted to be deleterious or likely deleterious by the CADD 26 , SIFT 27 , PolyPhen 28 and Condel prediction 29 methods (Table   S3 ).

Among the 41 coding variants identi ed at ACE2, the majority are rare (minor allele frequency, MAF < 0.05) in the pooled global population dataset ( Fig. 1A and Table S3 ). However, there are variants that are common (MAFs > = 0.05) in the Central African Hunter Gatherer (CAHG) population from Cameroon (often referred to as "pygmies") ( Fig. 1B) . One of these variants, rs138390800 (Lys341Arg), is a deleterious non-synonymous variant, and present at high frequency (MAF = 0.164) in the CAHG, while it is rare in other African populations and absent in non-African populations (Fig. 1C) . Two other nonsynonymous variants, rs147311723 (Leu731Phe) (MAF = 0.083) and rs145437639 (Asp597Glu) (MAF = 0.083), are also common only in the CAHG population (Figs. 1B and Table S3 ). These three nonsynonymous variants are the only common coding variants found at ACE2 in any of the populations examined.

We then investigated the potential role of these 41 coding variants in the conformation of the ACE2 protein. The 41 coding variants are distributed across the entire ACE2 protein ( Fig. 1D and Table S3 ), including its receptor-binding domain (RBD) region which binds to the SARS-CoV-2 spike protein, dimerization interface, and transmembrane helix. In particular, two novel non-synonymous variants Gly354Asp (chrX:15581230) and Ser43Asn (chrX:15600784) are both found directly in the RBD binding region of ACE2 ( Fig. 1D and Table S3 ); the former is only found in low frequency in one population, the Fulani from Cameroon (MAF = 0.008), and the latter is also an African speci c variant that is at low frequency in only three East African populations, two of which are Afroasiatic speaking populations from Kenya (MAF = 0.031) and Ethiopia (MAF = 0.012) ( Table S3 ). The variant Arg708Trp (rs776995986) occurs in the region identi ed as the TMPRSS2 cleavage site in ACE2 30 and is found only in the Afroasiatic speaking populations from Ethiopia (MAF = 0.004). Importantly, the presence of Arginine residues has been shown to be important in "multibasic" cleavage sites 18 . Therefore, due to the drastic change in physicochemical properties of the residue, this variation could be expected to interfere in TMPRSS2 cleavage e ciency, though it warrants experimental validation. Finally, two variants are located at glycosylation sites. Variant Asn546Ser (rs756905974, chrX:15572228), which causes the loss of a conserved glycosylation site on the ACE2 protein, is found only in the SAS populations (MAF = 0.001). Variant Lys26Arg (rs4646116), found in individuals from the European (EUR) (MAF = 0.005), African (AFR) (MAF = 0.001) and South Asian (SAS) (MAF = 0.002) populations from the 1KG dataset (Table S3) , occurs near both the conserved ACE2 glycosylation site Asn90 and the RBD binding site. The modi cation to a similarly positively charged positive residue could suggest a role for electrostatic interactions, though no direct interference with RBD binding could be deduced without further studies.

In contrast to coding variants which have direct effects on protein structure in all cells expressing a gene, the effects of regulatory genetic variants are relatively di cult to determine 31 . Expression quantitative trait locus (eQTL) analysis has been used to identify genetic variants associated with gene expression. We rst extracted 2,053 eQTLs signi cantly associated with ACE2 gene expression (P < 0.001) from the GTEx database 32 (Table S4) . To narrow down candidate functional variants, we focus on the eQTLs located in the promoter regions of target genes or in enhancers supported by chromatin interaction data 33 .

We identi ed six eQTLs (rs4830977, rs4830978, rs5936010, rs4830979, rs4830980 and rs5934263) located in a strong DNase peak at 73.3 kb upstream of ACE2 that have direct interactions with ACE2 based on RNA Pol2 ChIA-PET data (Fig. 1E, S2 and Table S4 ). All six SNPs are eQTLs of ACE2 and all of them have positive normalized effect sizes (NES > 0.2) and signi cant p-values (P < 0.00008) in brain, tibial nerve, tibial artery, pituitary and prostate cells ( Figure S3 and Table S4 ). In non-African populations, these six eQTLs are in high LD (R 2 = 0.91-1.0) ( Figure S4 ) and, thus there are two common haplotypes: "CCGGAT" and "ATCATC". The frequency for the "ATCATC" haplotype ranges from 0.31-0.47 in all populations except the East Asian population, which has a frequency of 0.068 at all 6 SNPs ( Figure S5 ). In African populations, LD is lower (R 2 > 0.5; Figure S4 ), and there are three common haplotypes: "CCGGAT" (0.564), "ATCATC" (0.308), and "CCCGAC" (0.116). Of note, every allele in the haplotype "CCGGAT" is correlated with higher expression of ACE2 in the cortex of the brain while alleles in haplotype "ATCATC" are correlated with lower expression of ACE2; other haplotypes have alleles with both positive and negative effect sizes in different tissues (Table S4) . Haplotype "CCCGAC" is only present in populations with African ancestry and its frequency is highest in the Botswana Khoesan (0.38) and Cameroon CAHG (0.38) populations. We also identi ed one variant (rs186029035) located in strong TF and DNase clusters (ENCODE) in the 16th intron of ACE2. This variant is only common in the Cameroon CAHG population and, therefore, there is no eQTL data for this SNP in the GTEx database (MAF = 0.153, Table S2 ).

Signatures of natural selection at ACE2

As indicated above, most of the non-synonymous variants at ACE2 are rare in global populations and many of them are predicted to be deleterious, indicating that this gene is under strong purifying selection. To formally test for signatures of natural selection at ACE2, we rst examined the ratio of non-synonymous and synonymous variants at each gene using the dN/dS test 34 . The dN/dS for all pooled samples was 0.77, indicating that ACE2 is under purifying selection globally (Table S5 and Figure S6 ). However, in the East Asian population, we observed seven non-synonymous variants (all of them are rare) and only one synonymous variant, and the dN/dS value is 1.85, indicating an excess of non-synonymous variation. In other populations, the dN/dS ratio ranges from 0 to 0.79 (Table S5 and Figure   S6 ). Thus, ACE2 appears to be under strong purifying selection in most populations but may be under weak purifying selection in the East Asian population. We next applied the MK-test 35 which compares the ratio of xed non-synonymous sites between humans and chimpanzee (Dn = 8) and xed synonymous sites (Ds = 6) to the ratio of polymorphic nonsynonymous sites among populations (Pn = 41) relative to polymorphic synonymous sites (Ps = 14) and found that it is not signi cant (odds ratio (OR) = 0.45, P = 0.94, two-sided Fisher's exact test, Table S6 and Figure S7 , S8).

Because the above-mentioned methods are more suitable for detecting signals of natural selection acting over long time scales 36 ; 37 , we then tested for signatures of recent positive selection at ACE2 in global populations using the iHS test 38 to detect extended haplotype homozygosity (EHH) 39 , which identi es regions of extended linkage disequilibrium (LD) surrounding a positively selected locus. We rst focused on the three common non-synonymous variants in the CAHG population from Cameroon (rs138390800, rs147311723 and rs145437639; MAF: 0.083 − .164), and a common putative regulatory variant (rs186029035, located in TF and DNase clusters in the 16th intron of ACE2, MAF = 0.153). The derived alleles of these variants exist on three different haplotype backgrounds: rs147311723 and rs145437639 are on the same haplotype backgrounds, while rs138390800 and rs186029035 are on similar, but distinct, haplotype background ( Fig. 2A) . The derived alleles of the corresponding SNPs on each haplotype background show EHH extending longer than 2 Mb, while the ancestral alleles of these SNPs harbor haplotypes extending less than 0.3 Mb (Fig. 2B) . We then calculated the integrated haplotype score (iHS) of each of these variants, to determine whether these extended haplotypes are unusually long compared to other SNPs with a similar allele frequency; the iHS values were not signi cant for any of these variants ( Figure S9 and Table S7 ). However, if selection were acting on multiple haplotypes simultaneously (as shown above), the EHH and iHS tests would not be well powered to detect selection 40 . We also used the d i statistic 41 to measure if allele frequencies at these candidate SNPs were strongly differentiated between Cameroon CAHG and other populations. The d i values of SNPs rs138390800 and rs186029035 were in the top 1.4% and 1.7%, respectively, of d i values for all SNPs examined, indicating that that allele frequencies at these variants are amongst the most highly differentiated in the CAHG population. However, it should be noted that in the CAHG these four variants (rs138390800, rs147311723, rs145437639 and rs186029035) are in complete LD based on D' (D' = 1) with the 6 eQTLs described above ( Figure S10 , S11), indicating that the alleles are on the same haplotype background. Thus, it is not possible to distinguish if the non-synonymous variants are targets of selection or if they are "hitchhiking" to high frequency due to selection on anking regulatory variants. Given the high LD in the region, it is possible that multiple functional variants on the same haplotype backgrounds have been under selection.

We then investigated signatures of recent positive selection at candidate regulatory variants near ACE2 in the global datasets. In total, there are 234 variants that had high iHS scores (|iHS| > 2) in at least one population extending over an ~ 200 kb region (Table S8) , and 48% (n = 113) of these variants are either eQTLs or located at DNase hypersensitive regions which are in high LD based on D' (Figure S10, S11, and Table S8 ). Among the region near the TSS (< 10kb from ACE2), there are two variants in high LD (D' = 1) that had high iHS scores in the San population from Botswana (Fig. 3A ); rs150147953 is located in a DNase peak in multiple tissues including lung, intestine and heart and rs2097723 is an eQTL of ACE2 in the brain (Fig. 1E , S12; Table S8 ). We also identi ed strong selection signals at the region 50-120 kb upstream of ACE2 (chrX: 15650000-15720000) in the AFR, San from Botswana, and Niger-Congo-speaking populations from Cameroon, as well as Afroasiatic-and Nilo-Saharan-speaking populations from Kenya ( Fig. 3A and S8 ). Two SNPs in this region (rs5936010 and rs5934263) have elevated iHS scores (|iHS| > 2) in the San population from Botswana and the Afroasiatic population from Kenya (Fig. 3A ) and are part of the 6 eQTLs described above, located within a strong enhancer interacting with the promoter of ACE2 (Fig. 1E) . Two additional eQTLs, that are in complete LD with the 6 eQTLs (D' = 1; Figure S11 ), rs4830984 and rs4830986, had high iHS scores in four of the ve African populations listed above (all but the Kenya Afroasiatic; Fig. 3A ).

We performed haplotype network analysis to examine phylogenetic relationships among haplotypes at ACE2 in global populations derived for SNPs showing signatures of natural selection ( Fig. 3B and 3C ). We identi ed two haplotype clades: one (clade 1) is nearly speci c to Africans and the other (clade 2) encompasses global populations (Fig. 3B ). In the CAHG, haplotypes containing the rs138390800 (Lys341Arg) non-synonymous variant and the rs186029035 regulatory variant are in clade 1, whereas haplotypes containing the rs147311723 (Leu731Phe) and rs145437639 (Asp597Glu) non-synonymous variants are located in clade 2 (Fig. 3B ). Haplotypes containing the two regulatory variants (rs5936010 and rs5934263) located 50-120 kb upstream of ACE2 are shared in global populations, and the nearby regulatory variants rs4830984 and rs4830986 are sub-lineages on those haplotype backgrounds ( Fig. 3B and 3C ).

We examined associations of genetic variation at ACE2 with clinical phenotypes using the PMBB cohort that consists of exomesequencing data from 15,977 participants between the ages of 19 and 89 years (52% female) with extensive clinical data available through their electronic health records (EHR). Of these, 7061 individuals were of European ancestry (42%) and 8916 were of African ancestry (55%) ( Table S1 ).

To test for association between rare coding variants and clinical phenotypes, we applied a gene-based approach 42; 43 and single variant analysis. First, we performed a gene-based analysis by collapsing the coding region variants with MAF < 0.01 that are annotated as nonsynonymous or putative loss-of-function (pLOF) variants. We tested for association with 12 phenotypes, encompassing COVID-relevant disease classes affecting different organ systems, de ned by EHR based diagnosis codes (Table S9 ). For the gene-based approach, we applied two statistical tests: a) a burden test (i.e. the cumulative effect of rare variants in a gene) that uses logistic regression and b) a sequence kernel association test (SKAT) 44 . Thus, it can compute effect estimates but may suffer from loss of power when gene variants have effects in opposite directions (i.e., protective and higher risk variants). This limitation can be overcome by parallel analysis with SKAT, a powerful approach to model mixed effect variants. However, this approach does not provide effect estimates. Therefore, we reported outcomes using both methods. Ancestry speci c analysis of gene-based tests identi ed seven associations in African ancestry (AA) and three associations in European ancestry (EA) populations that reached statistical signi cance levels after multiple hypothesis correction (p < 1 x 10 − 04 ) for the SKAT model. None of the gene burden models reached a signi cance level of p < 1 x 10 − 04 . The effect size from the logistic regression model was used to indicate a protective or increased risk effect on disease phenotype. In the AA population, the most signi cant associations were with hepatic encephalopathy and respiratory failure ( Fig. 1F and Table 1 ). The association with respiratory failure is interesting as it is one of the key severe clinical features reported for COVID-19 10; 45-48 . However, the same association was not signi cant in the EA population, which could be explained by lack of power due to lower number of coding variants at ACE2 in EA. Within the EA population, the most signi cant associations included hepatic coma, respiratory syncytial virus infectious disease, and cirrhosis of the liver (Table 1) . 

We also examined an extended list of ~ 1800 phecodes derived from the EHR and 33 EHR-based quantitative lab measurements and performed a phenome-wide association study (PheWAS) 42; 43; 49 . After multiple testing correction, we identi ed one association in the AA and ve associations in the EA populations reaching study-wide signi cance (p < 1 x 10 − 5 ) (Table S9 and S5) . Myocarditis, a rare cardiovascular disease caused by viral infection, was the top PheWAS association in the AA population but not signi cant in the EA population. Although the population difference for this speci c association is unclear, recent studies have reported a link between SARS-CoV-2 induced cardiac injury among COVID-19 patients 50 , which it was suggested might be mediated by ACE2. This observation would be consistent with ACE2 expression in heart tissue, and its upregulation in cardiomyocytes [50] [51] [52] . Among respiratory diseases, cough and allergic rhinitis reached nominal signi cance (p < 0.01) in the AA population (Table S9 ). In the EA population, we identi ed a nominal association with in uenza, asthma, emphysema, cough, and painful respiration (p-value < 0.01). Our ndings in the EA cohort are consistent with other studies of ACE2 in subjects derived from the UK biobank 53 . Among the median measure of 33 EHR-based quantitative lab measurements that we investigated (see Methods), only the internationalized normalized ratio (INR) derived from the prothrombin time test showed a nominal association with increase in INR above 1.11, potentially relevant to blood clotting abnormalities observed in COVID patients (Table 2) . For the six eQTLs identi ed near ACE2 (rs4830977, rs4830978, rs5936010, rs4830979, rs4830980 and rs5934263), we performed a PheWAS with clinical data by ancestry. We found that two of the six eQTLs ( Table S10 ). Among the respiratory disorders, all six eQTLs had nominal associations (p < 0.01) with acute sinusitis and dypnea (shortness of breath) in AA and bronchiectasis in EA. Further, we noticed a difference in the effect of association among the six eQTLs with respiratory disorders examined in AA. Variants rs5936010 (OR = 1.11) and rs5934263 (OR = 1.19) were associated with increased risk of respiratory disorder, whereas the rest of the four eQTL variants were associated with decreased risk.

Genetic variation at TMPRSS2 and its potential role in SARS-COV-s2 infection susceptibility

The trans-membrane protease serine 2 (TMPRSS2) protein enhances the spike protein-driven viral entry of SARS-CoV-2 into cells 18 Table S11 ). In addition, some non-synonymous variants were common and speci c to African populations. Notably Table S11 ). Another non-synonymous variant rs61735790 (His18Arg) is common in the CAHG populations from Cameroon (MAF = 0.12) and the Nilo-Saharan populations from Ethiopia (MAF = 0.12) but is rare in other populations ( Fig. 4B and Table S11 ).

We identi ed two regulatory SNPs (rs76833541 and rs4283504) in the promoter region of the TMPRSS2 gene that have been identi ed as eQTLs of TMPRSS2 in testis (Fig. 4D , S13, and Table S4 ). The MAF of rs76833541 is higher in EUR (MAF = 0.16) than other populations (EAS = 0.002, AFR = 0.006, AMR = 0.06 and SAS = 0.05) and the MAF of rs4283504 is more common in EAS (MAF = 0.21) than other populations (EUR = 0.11, AFR = 0. 04, AMR = 0.12 and SAS = 0.14) ( Figure S14 and Table S2 ).

We applied the MK test at TMPRSS2 and observed that Dn/Ds (13/2) is signi cantly larger than Pn/Ps (48/45) among pooled human samples (OR = 6.1, P-val = 0.009, Fisher's exact test) (Fig. 5A , and Table S6 ) as well as in individual ethnic groups (OR ranged from 5.0-17), indicating positive selection in the hominin lineage after divergence from chimpanzee. Notably, there are 13 non-synonymous and 2 synonymous variants at TMPRSS2 (ENST00000398585.7, see Figure S15 for ENST00000332149.10) that were xed in human populations. The non-synonymous variants are located in different structural domains of TMPRSS2: amino acid A3P, N10S, T46P, A70V, R103C, and M104T are located in the cytoplasmic region which may function in intracellular signal transduction 54 ; L124I is located in the transmembrane region; N144K is located in the extracellular region; S165N and S178G are located in the LDL-receptor class A domain;

E441Q and T515M are located in the Peptidase S1 domain which is involved in the interaction with the SARS-CoV-2 spike protein 18 ;

S529G is located in the last amino acid position of the protein (Fig. 5B) . In contrast to the MK test, the dN/dS ratio test was not signi cant in any population, indicating no excess of non-synonymous to synonymous variation within populations. (Table S5 and Figure S6 ).

We also tested for recent positive selection at TMPRSS2 in all ethnic groups using iHS ( Figure S16 and Table S7 ). We found many SNPs (n = 153) with high iHS scores (|iHS| > 2) in different ethnic groups in a 78 kb region encompassing the TMPRSS2 gene which show high levels of LD (ChrX:41454000-41541000; Figure S16 , S17). We identi ed a non-synonymous variant (rs150969307) that shows a signature of positive selection (iHS = 2.01) and is common only in the Chabu hunter gatherer population from Ethiopia (MAF = 0.079) (Table S11 ). We found that more than one third of SNPs with |iHS| scores > 2.0 (62 of 153) are located in putative regulatory regions ( Figure S18 and Table S8 ).

In the PMBB, gene-based analysis with 12 severe disease classes identi ed nominal associations with respiratory failure, respiratory syncytial virus infectious disease, lower respiratory tract infection and pneumonia in the AA population but no statistically signi cant association in the EA population (Table 1 , Fig. 4E ). As with ACE2, the clinical phenotype associations with TMPRSS2 in AA may be driven by an excess of rare variants in that population and, hence, more carriers in comparison to EA. Among the diseases in the respiratory disorder category, we identi ed a nominal association (p < 0.01) with allergic rhinitis in AA and with obstructive bronchitis in EA populations (Table S9) . Previously, a gene-based PheWAS with EHR-derived disease codes in the UK biobank population, which consists of mostly individuals of European descent, showed no statistically signi cant associations with TMPRSS2 55 . Among clinical lab measures, we identi ed nominal association with urine bilirubin levels (p = 0.001). The PheWAS of the two regulatory eQTLs (rs76833541 and rs4283504) of TMPRSS2 described above identi ed association of rs76833541 with abnormal glucose (p = 8.9 x 10 − 4 , OR = 1.5) in EA and rs4283504 with glucocorticoid de ciency (p = 0.001, OR = 2.7) in AA (Fig. 4F) . We did not identify any association between these two eQTLs and respiratory conditions (Fig. 4F , and Table S10 ).

DPP4 DPP4 is a receptor for the Middle East Respiratory Coronavirus (MERS-Cov) and was reported to interact with SARS-CoV-2 56 . At this gene, we identi ed 47 non-synonymous variants and one loss-of-function variant (Table S12) . Among them, no variant was common in the pooled global dataset (Fig. 6A) , suggesting this gene is extremely conserved during human evolutionary history. Only one nonsynonymous variant (rs1129599, Ser437Thr) was common in the Fulani pastoralists from Cameroon (MAF = 0.081), was present at low frequency in other African populations, and was absent in non-African populations ( Fig. 6B and 6C ). In addition to the nonsynonymous variants, one loss-of-function variant was identi ed at DPP4. The variant rs149291595 (Q170*) has low MAF in some African populations (MAF < 0.05) but is absent in non-African populations.

We identi ed four eQTLs (rs1861978, rs35128070, rs17574 and rs13015258) in the promoter region of the DPP4 gene (Fig. 6D) . Three of the variants (rs1861978, rs35128070 and rs17574) are signi cant eQTLs in the transverse colon and rs13015258 is an eQTL in the lung (P < 5.9e-6, Figure S20 and Table S4 ). The minor alleles of these three variants are rare in EAS (MAF < 0.05) but common in all other populations (MAF > 0.15, Figure S21 , and Table S2 ). The fourth SNp, rs13015258, resides in the center of a cluster of DNase peaks identi ed in ENCODE (Fig. 6D ) with MAF ranging from 0.38 in the AMR population to 0.6 in other populations ( Figure S21 and Table S2 ).

The MK-test result was not signi cant in either the pooled samples (Dn = 3, Ds = 5, Pn = 45, Ps = 33 OR = 0.44, P = 0.9, two-sided Fisher's exact test) nor in each population separately (Table S6 and Figure S8 ). For the the dN/dS test, we observed ratios ranging from 0 to 0.52 in individual populations, indicating that DPP4 is highly conserved (Table S5 and Figure S6 ) within human populations. Using the iHS test, we identi ed 8 SNPs that had extreme high iHS scores (|iHS| > 2) in the Khoesan populations from Botswana ( Figure S22 and Table S7 ).

Five of these SNPs (rs10166124, rs2284872, rs2284870, rs7608798 and rs2160927) are in LD (D' > 0.95) with each other ( Figure S23 ). The SNP rs2284870 is located in a strong DNase peak in heart tissue ( Figure S24 and Table S8 ).

In the gene-based analysis among AA PMBB participants, we identi ed signi cant associations (only in the SKAT model) with respiratory syncytial virus infectious disease and upper respiratory tract disease (Fig. 6E , Table 1 We identi ed three regulatory eQTLs (rs13252864, rs17061979 and rs114909654) located within 2 kb of the transcription start site of LY6E (Fig. 7D) , all of which are signi cant in esophageal mucosa (P < 1e-5, Figure S25 and Table S4 ), which has a high expression level of LY6E (TPM = 108, GTEx). The minor alleles of rs13252864 and rs114909654 are common in African populations (MAF > 0.15) while very rare in other populations (MAF < 0.02, Figure S26 ), whereas the MAF of rs17061979 is relatively high in EAS (0.18) and SAS (0.13) and rare in other populations (MAF < 0.05, Figure S26 ).

The MK-test result was not signi cant in either the pooled samples (Dn = 0, Ds = 4, Pn = 9, Ps = 9, OR = 0, P = 0.9, two-sided Fisher's exact test) nor in each population separately (OR ranging from 0 to 0.52; Table S6 and Figure S8 ), indicating that LY6E is highly conserved. We identi ed 19 variants that that had extreme high iHS scores (|iHS| > 2) (Table S7, Figure S27 ), some of which are in LD in speci c populations ( Figure S28 ). One variant (rs867069115) shows an extreme iHS score in the Hadza hunter-gatherer population from Tanzania (iHS = -2.94). This variant is located in a regulatory region ~ 1.9kb downstream of LY6E, within DNase and TF peaks in the lung, intestine, kidney, heart, stomach, pancreas and skeletal muscle from ENCODE ( Figure S29 ) and is common only in the Hadza population (MAF = 0.14), is rare in other African population (MAF < 0.05) and is absent in all non-African populations (Table S2) . SNP rs10283236, which shows an extreme iHS value in the CEU population, is an eQTL of LY6E located within DNase and TF clusters identi ed in ENCODE (~ 4.14kb downstream of LY6E) active in many tissues including lung, kidney and small intestine.

We identi ed a nominal association between LY6E with pneumonia in the AA population only (p = 0.01, Fig. 7E , Table 2 and Table S9 ). LY6E also has nominal association (p < 0.01, Table 2 ) with total cholesterol, prothrombin, and eosinophil levels among the AA population. Association with prothrombin is not statistically signi cant in the EA population. The association analysis of regulatory variants identi ed most signi cant association with "severe protein-calorie malnutrition" (p = 2.35 x 10 − 05 , OR = 1.9) and "acute post hemorrhagic anemia" (p = 6.4 x 10 − 04 , OR = 1.6) in the AA population. In the EA population, "chronic ulcer of skin" with rs13252864 (p = 0.001, OR = 2.2) was the most signi cant association (Fig. 7F , and Table S10 ).

Investigating global patterns of genetic variation at genes that play a role in SARS-CoV-2 infection could provide insights into potential differences in susceptibility to COVID-19 among diverse human populations. However, African populations are under-represented in the majority of current genetic studies of COVID-19 susceptibility and severity, despite the fact that they have the highest genetic diversity among human populations 57; 58 . In this study, we present a comprehensive analysis of human genes which play a key role in SARS-CoV-2 host receptor binding and cellular invasion, i.e., ACE2, TMPRSS2, DPP4, and LY6E. We characterized the coding and non-coding variants in these candidate genes to examine population differences in allele frequencies and signatures of natural selection in diverse ethnic populations. This included novel sequence data from 2012 ethnically diverse African populations from ve countries (Cameroon, Ethiopia, Kenya, Botswana and Tanzania) in Africa practicing different lifestyles (e.g. hunter-gatherers, agriculturalists, and pastoralists).

Additionally, we analyzed the correlation of common and rare genetic variants in these four genes with clinical traits derived from the dataset of 15,997 individuals from the Penn Medicine BioBank (PMBB) with African and European ancestry. We included 12 "organ dysfunction" categories de ned by phenotype algorithms (see Methods), ~ 1800 ICD diagnosis codes, and 33 laboratory test measures from the EHR. Our results highlight the importance of including genomes from diverse ethnic groups in human genetic studies.

At ACE2 we identi ed 41 non-synonymous variants, most of which are rare, suggesting that they are under purifying selection. Tests based on dN/dS indicate that East Asians have an excess of non-synonymous variation at ACE2, indicating weak purifying selection has in uenced patterns of variation in that population. However, there are some variants that are common in speci c ancestry groups. Notably, we identi ed three common non-synonymous variants (rs138390800, rs147311723, and rs145437639) at ACE2 with MAF ranging from 0.083 to 0.164 in Central African hunter-gatherers (CAHG), which were the only common coding variants (de ned here as MAF > 0.05)

found in global populations studied here and by others 20; 53; 59; 60 . We observed that the derived alleles of the common non-synonymous SNPs (rs138390800, rs147311723, rs145437639) and one putative regulatory variant (rs186029035) at ACE2 in CAHG show evidence of EHH, with the extended haplotypes extending longer than 2 Mb, though they did not show deviation from neutrality based on the iHS test.

However, we do not have much power to detect a selection signal using this test because the SNPs are on three different haplotype backgrounds in CAHG, possibly due to selection on existing variation (e.g."soft selection") which decreases the power to detect signi cant iHS scores. Moreover, each haplotype is at a relatively low frequency (0.083 to 0.164), which further reduces the power of the iHS test. The The expression of ACE2 and TMPRSS2 in nasal and bronchial epithelial cells is higher in adults than children, and in healthy individuals compared with smokers or patients with chronic obstructive pulmonary disease 51 . Therefore, differences in expression levels of ACE2 and TMPRSS2 could in uence the susceptibility and host reactions to SARS-CoV-2. Regulatory eQTLs that differ in frequency across ethnically diverse populations may play a role in local adaptation and disease susceptibility 67 . eQTL mapping has been used to identify populationspeci c regulatory variation and revealed the association of regulatory alleles with complex traits such as multiple sclerosis 68 , malaria 54 and immune response to infection 69 . We identi ed regulatory eQTLs associated with ACE2, TMPRSS2, DPP4, and LY6E gene expression and highlighted the eQTLs showing highly differentiated MAF among populations and/or signatures of natural selection. These eQTLs are located in ChIP-seq and DNase peaks and have the potential to in uence transcription factor binding and, thus, change the promoter or enhancer activities in speci c tissues 70; 71 . Interestingly, some of the eQTLs in the upstream regions of ACE2 were under selection in African populations. For example, rs5936010 and rs5934263, which are located within a strong enhancer interacting with the promoter of ACE2 as suggested by ChIA-PET, harbored signi cant iHS scores (|iHS| > 2) in both Afroasiatic populations from Kenya and the San population from Botswana. Further, PheWAS of these eQTLs in the PMBB populations identi ed association of eQTLs at ACE2 with type 2 diabetes (rs5936010) and hypertension (rs5934263). These are known pre-existing conditions that increases risk of severe illness due to testing of predicted regulatory variants will provide insights into differences in gene expression regulation at ACE2, TMPRSS2, DPP4, and LY6E among different populations. In the future, eQTL mapping in diverse populations will be informative for identifying novel trait associations that may differ in prevalence across ethnic groups 75 .

The gene-based genetic association analyses of non-synonymous variants at ACE2, TMPRSS2, DPP4 and LY6E identi ed several associations with clinical phenotypes. We observed that respiratory failure has signi cant association with ACE2 and TMPRSS2 among the PMBB AA population. That is a particularly interesting nding as respiratory failure is one of the clinical outcomes observed in some patients with COVID-19 10; 45-48 . However, this association was not signi cant in the EA population. This observation could be explained by the low number of coding variants and carriers at ACE2 and TMPRSS2 among EA and, hence, low power to detect an association. An association with myocarditis, a rare cardiovascular disease caused by viral infection, was also observed in the AA population. Recent studies have reported a link between SARS-CoV-2 induced cardiac injury such as myocarditis among COVID-19 patients 76 . Further, ACE2 has known expression in heart tissue, and it plays an important role in transcriptional dysregulation in cardiomyocytes -cells that make up cardiac muscles [50] [51] [52] . We observed association between ACE2 and myocarditis only in the AA population but as noted above, we may not have as much power to detect and association in EA. Blood clotting abnormalities in lungs and other organs in COVID-19 patients have been reported by several studies 77 . In autopsies of COVID-19 patients, thrombosis was found to be a prominent nding across multiple organs, even in spite of extensive anticoagulation treatment and regardless of timing of clinical progression, indicating that thrombosis might be at play in the early stages of disease 77 . One hypothesis to explain this observation is that the dysfunction of endothelial cells may play an important role in increased risk of thrombosis 78 . We observed associations between the internationalized normalized ratio (INR) derived from the prothrombin time test (PT) with ACE2 and LY6E in a gene-based association test. The INR test measures the time it takes blood to clot and is an important measure for individuals with blood clotting disorders or on blood thinners.

Characterizing the genetic variation and clinical phenotype associations at these four genes that play a key role in SARS-CoV-2 infection could be relevant for understanding individual and population differences in infection susceptibility. We performed evolutionary analyses to dissect the forces underlying global patterns of genetic variation and identi ed variants that may be targets of selection. It will be important to determine the functional effects of these candidate adaptive variants using in vitro and in vivo approaches in future studies. Additional studies will be needed to investigate the impact of genetic variation in modulating susceptibility/resistance to SARS-CoV-2 infection and other coronaviruses across ethnically diverse populations.

The genomic data used in this study were from three sources: the Africa 6K project (referred to as the the "African Diversity" dataset) which is part of the TopMed consortium 79 , the 1000 Genomes project (1KG) 25 Public Health. Whole genome sequencing (WGS) was performed to a median depth of 30X using DNA isolated from blood, PCR-free library construction and Illumina HiSeq X technology, as described elsewhere 79 . In the 1KG data set, 2504 genome sequences from phase 3 25 were included in our analysis.

The PMBB participants were recruited through the University of Pennsylvania Health System by enrolling at the time of clinic visit. Patients participate by donating either blood or a tissue sample and allowing researchers access to their EHR information. This academic biobank has DNA extracted from blood that has been genotyped using an Illumina In nium Global Screening Array-24 Kit version 2 and whole exome sequencing (WES) using the IDT xgen exome research panel v1.0. The study cohort consisted of 15,977 individuals total, with 7,061 of European ancestry (EA) and 8,916 of African ancestry (AA) (Table S1 ). Genetic ancestry of these samples was determined by performing quantitative discriminant analyses (QDA) on eigenvectors. The 1000 Genomes datasets with super population ancestry labels (EUR, AFR, EAS, SAS, Other) were used as QDA training datasets to determine the genetic ancestry labels for the PMBB population. We identi ed and removed 117 related individuals using a kinship coe cient of 0.25.

We used Ensembl Variant Effect Predictor (VEP) for variant annotations 80 (Table S2 ). For whole-exome genomes from the PMBB dataset, annotations were restricted to coding regions only. For gene-based association analysis using the PMBB dataset, we collapsed all the predicted non-synonymous variants with REVEL score > 0.5 and putative loss of function variants (pLOFs) with MAF < 0.01. We assigned variants as pLoFs if the variant was annotated as stop_lost, missense_variant, start_lost, splice_donor_variant, inframe_deletion, frameshift_variant, splice_acceptor_variant, stop_gained, or inframe_insertion. All genome coordinates followed the GRCh38 assembly.

We identi ed regulatory variants likely to impact the target genes. For all four genes (ACE2, TMPRSS2, DPP4 or LY6E), we extracted the variants located within ± 10kb distance to their TSS as well as enhancers supported by RNA Pol2 ChIA-PET data from ENCODE 81 . These variants were further ltered by overlapping with DNase-seq and ChIP-seq peaks from Roadmap 82 , ENCODE 81 , Remap2 83 ; or overlapping with signi cant single-tissue expression quantitative trait locus (eQTLs) (P-value < 0.001) from the GTEx V8 database 32 . We visualized the location of these regulatory and eQTL variants using the UCSC genome browser and highlighted the variants using Adobe Illustrator.

In this analysis, we focused on the phenotypes characterized as primary organ dysfunctions in the early studies on COVID-19. Broadly, we centered our analyses on these four broad clinical conditions/phenotypes: respiratory injury/failure, acute liver injury/failure, acute cardiac injury/failure, and acute kidney injury/failure. These disease classes are well characterized in human disease ontologies such as Monarch Disease Ontology (MONDO). MONDO merges multiple disease resources such as SNOMED, ICD-9, and ICD-10. We leveraged the existing mappings between ICD-9/10 codes (which are how the data are coded in the EHR) and the MONDO disease classes for the conditions described above. We identi ed 12 MONDO classes that are closely related to four conditions of interest (Table S1 ). By using ICD-9 and ICD-10 data from the EHR of the PMBB participants, we mapped the ICD codes to 12 MONDO disease classes. Details on the ICD code mapping to MONDO disease classes are provided in Table S14 . Individuals were de ned as cases if they had at least one instance of any ICD code mapped to a MONDO disease class or as controls if they had no instance of the code in that disease class. A clinical expert on our team manually reviewed the MONDO and ICD-9/10 mappings.

We also used EHR phenotypes de ned by groupings of ICD-9 and ICD-10 codes into clinically relevant groups, called phecodes, used in prior PheWAS studies 84 . Individuals with two or more instances of a phecode were de ned as cases, whereas those with no instance of a phecode were de ned as controls. Individuals with only one instance were excluded for that phecode. A total of 1860 phecodes were included in the study.

Additionally, we extracted data on 34 clinical laboratory measures for PMBB participants from the EHRs. We derived a median value for each laboratory measure based on all clinical tests ever done within the Penn Medicine health system. Any measurement value that falls more than three standard deviations from the normal were labeled as outliers and removed.

We used the R SKAT package for conducting a gene-based dispersion test and Biobin 42; 85 for gene burden analysis. Here, multiple genetic variations in a gene region were collapsed to generate a gene burden/dispersion score and regression methods were used to test for association between the genetic score and a phenotype or trait. We performed three separate burden analysis for 12 MONDO disease classes (Table S14) , 1860 phecode, and 34 clinical lab measures. Brie y, the variants annotated as non-synonymous (REVEL score > = 0.5) and pLoFs within each of the four candidate genes were collapsed into their respective gene regions (ACE2, TMPRSS2, DPP4 and LY6E). For both statistical dispersion and burden tests, models were adjusted by the rst four principal components of ancestry, sex, and decade of birth. For multiple hypothesis correction, a conservative Bonferroni adjustment was used to derive a signi cant p-value threshold (pvalue < 0.0001). We also performed a univariate statistical test for each of the rare variants from these four candidate gene regions to study the effects of each single nucleotide variant (SNV) on the disease phenotype. after divergence from our closest ancestor, the chimpanzee, the ratio of nonsynonymous to synonymous variation within species is expected be larger than the ratio of nonsynonymous to synonymous variation between species (i.e. Dn/Ds > Pn/Ps). If there is positive diversifying selection among human populations but conservation of xed differences between species, the ratio of nonsynonymous to synonymous variation between species should be lower than the ratio of nonsynonymous to synonymous variation within species (i.e.

Dn/Ds < Pn/Ps). The chimpanzee sequence (Clint_PTRv2/panTro6) used in the analysis was obtained from the UCSC genome browser. We also used the ratio of substitution rates at non-synonymous and synonymous sites (dN/dS) to infer selection pressures on the four candidate genes, as the dN/dS ratio has more power to detect recurrent positive selection 88 and In our analysis, for each population, we estimated the total number of synonymous (S d ) and non-synonymous (N d ) differences, and then calculated dN/dS. If dN/dS is larger than one, it suggests positive diversifying selection in uencing variation at the gene. If dN/dS is less than one it suggests the gene is evolutionary conserved.

Genomic regions that have undergone recent positive selection are characterized by extensive linkage disequilibrium (LD) on haplotypes containing the mutation under selection. We used the extended haplotype homozygosity (EHH) 39 

This is a list of supplementary les associated with this preprint. Click to download. 

The hallmarks of COVID-19 disease

Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic

Demographic perspectives on the mortality of COVID-19 and other epidemics

The age distribution of mortality from novel coronavirus disease (COVID-19) suggests no large difference of susceptibility by age

Biological sex impacts COVID-19 outcomes

Prevalence of Asymptomatic SARS-CoV-2 Infection

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

COVID-19 and African Americans

Racial Disparities-Associated COVID-19 Mortality among Minority Populations in the US

Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA : the journal of the

Characteristics of and Important Lessons From the Coronavirus Disease

Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

EXPRESS: Global Impact of the COVID-19 Pandemic on Stroke Hospitalizations and Mechanical Thrombectomy Volumes

COVID19 and ischemic stroke: Mechanisms of hypercoagulability (Review)

Evidence of Coronavirus (CoV) Pathogenesis and Emerging Pathogen SARS-CoV-2 in the Nervous System: A Review on Neurological Impairments and Manifestations

Ischaemic stroke as an initial presentation in patients with COVID-19: evaluation of a case series in an emergency in Brazil

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations

Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system?

SARS and MERS: recent insights into emerging coronaviruses

A global reference for human genetic variation

CADD: predicting the deleteriousness of variants throughout the human genome

SIFT: Predicting amino acid changes that affect protein function

Predicting functional effect of human missense mutations using PolyPhen-2

Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein

Realizing the signi cance of noncoding functionality in clinical genomics

The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans

Higher-order chromatin domains link eQTLs with the expression of far-away genes

Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions

Adaptive protein evolution at the Adh locus in Drosophila

Positive natural selection in the human lineage

The population genetics of dN/dS

A map of recent positive selection in the human genome

Genome-wide detection and characterization of positive selection in human populations

Recent human adaptation: genomic approaches, interpretation and insights

Tracking footprints of arti cial selection in the dog genome

BioBin: a bioinformatics tool for automating the binning of rare variants using publicly available biological knowledge

Optimal uni ed approach for rare-variant association testing with application to small-sample case-control wholeexome sequencing studies

Rare-variant association testing for sequencing data with the sequence kernel association test

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Rare variants in drug target genes contributing to complex diseases, phenome-wide

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan

Recognizing COVID-19-related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management

Myocyte-Speci c Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2-Mediated Myocarditis

Revealing variants in SARS-CoV

Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes

Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26

The genetic structure and history of Africans and African Americans

The Missing Diversity in Human Genetic Studies

New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis

gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population

Adaptive, convergent origins of the pygmy phenotype in African rainforest hunter-gatherers

Estimation of divergence times for major lineages of primate species

Structure, function and variants analysis of the androgenregulated <em>TMPRSS2</em>, a drug target candidate for COVID-19 infection

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

The pivotal link between ACE2 de ciency and SARS-CoV-2 infection

Genetic architecture of gene expression traits across diverse populations

Population-and individual-speci c regulatory variation in Sardinia

No evidence that selection has been less effective at removing deleterious mutations in Europeans than in Africans

DNase I sensitivity QTLs are a major determinant of human expression variation

Integrative modeling of eQTLs and cis-regulatory elements suggests mechanisms underlying cell type speci city of eQTLs

Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study

COVID-19 in people with diabetes: understanding the reasons for worse outcomes

Genetic effects on gene expression across human tissues

Discovery of novel hepatocyte eQTLs in African Americans

Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus

Blood clots in COVID-19 patients: Simplifying the curious mystery

Megakaryocytes and platelet-brin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series

EClinicalMedicine 24

The Ensembl Variant Effect Predictor

An integrated encyclopedia of DNA elements in the human genome

The NIH Roadmap Epigenomics Program data resource

ReMap 2020: a database of regulatory regions from an integrative analysis of Human and Arabidopsis DNA-binding sequencing experiments

PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations

Knowledge Driven Binning and Phewas Analysis in Marsh eld Personalized Medicine Research Project Using Biobin

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

VMD: visual molecular dynamics

An investigation of the statistical power of neutrality tests based on comparative and population genetic data

selscan: an e cient multithreaded program to perform EHH-based scans for positive selection

Fast and accurate long-range phasing in a UK Biobank cohort

Expanded encyclopaedias of DNA elements in the human and mouse genomes

POPART: full-feature software for haplotype network construction

Molecular data for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Genome Sequencing for "NHLBI TOPMed: Integrative Genomic Studies of Heart and Blood Related Traits in Africans (Africa6K) " was performed at Broad Genomics (hhsn268201600034i). Core support including centralized genomic read mapping and genotype calling, along with variant quality metrics and ltering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Core support including phenotype harmonization, data management, sample-identity QC, and general program coordination were provided by the TOPMed Data Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001I). We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed.Funding for this study was provided by grant numbers: X01HL139409, 1R35GM134957, R01GM113657, R01DK104339, ADA 1-19-VSN-02,

We used d i statistics to identify SNPs that are highly differentiated in allele frequency between populations based on unbiased estimates of pairwise F ST 41 . The d i statistics were performed cross the 40Mb regions. If the candidate SNP was within the top 5% of the 40Mb regions in a speci c population, the SNP was considered as a variant showing signi cant differentiation between the target population and other populations. These variants are candidate SNPs that show signals of local adaptation.Haplotype networks were constructed by PopART 92 using the built-in minimum spanning algorithm.

No con ict of interest